Login to Your Account

Clinic Roundup

Monday, September 12, 2011
• Roche AG, of Basel, Switzerland, said it started a Phase I trial of an investigational molecule designed to address the cognitive and behavioral deficits associated with Down syndrome by targeting the gamma-amino butyric acid system. The study will recruit adults with Down syndrome between the ages of 18 and 30, and will assess the drug's safety and tolerability.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription